E. Anastasopoulou

发表

AE37 peptide vaccination in prostate cancer: identification of biomarkers in the context of prognosis and prediction

S. Perez, M. Papamichail, C. Baxevanis, 2014, Cancer Immunology, Immunotherapy.

Estimation of maspin's subcellular localization in invasive ductal breast cancer via light microscopy and computerized image analysis: a comparative study.

P. Korkolopoulou, E. Patsouris, G. Zografos, 2013, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4+ T-cells

S. Perez, M. Papamichail, C. Baxevanis, 2016, Oncoimmunology.

Evaluation of the Effect of Aspirin on Platelet Aggregation: Methodological Recommendations for Aspirin-Drug Interaction Studies

M. Moerland, J. Burggraaf, A. Kruithof, 2015 .

Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide

S. Perez, M. Papamichail, C. Baxevanis, 2016, Journal of Immunotherapy for Cancer.

AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial

H. Kalbacher, S. Perez, C. Baxevanis, 2013, Cancer Immunology, Immunotherapy.

Immune profiling of melanoma tumors reflecting aggressiveness in a preclinical model

S. Perez, C. Baxevanis, I. Voutsas, 2017, Cancer Immunology, Immunotherapy.

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.

J. Murray, E. Mittendorf, G. Peoples, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Further insight into AE37 peptide vaccination in prostate cancer

I. Voutsas, E. Anastasopoulou, 2017, Future science OA.

Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence

J. Murray, E. Mittendorf, G. Peoples, 2020, Breast Cancer Research and Treatment.

Immune biomarkers: how well do they serve prognosis in human cancers?

S. Perez, M. Papamichail, C. Baxevanis, 2015, Expert review of molecular diagnostics.

A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit

H. Kalbacher, S. Perez, M. Papamichail, 2015, Cancer Immunology, Immunotherapy.

Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer

G. Pawelec, N. Arnogiannaki, S. Perez, 2017, Journal of Immunotherapy for Cancer.

Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer.

G. Pawelec, N. Arnogiannaki, S. Perez, 2017, Journal for immunotherapy of cancer.

DRB1*11 allele expression and HER2 pre-existing immunity may predict benefit in breast cancer patients vaccinated with the HER2 modified AE37 peptide vaccine

E. Mittendorf, G. Peoples, S. Perez, 2015, Journal of Immunotherapy for Cancer.

Potential Prognostic Molecular Signatures in a Preclinical Model of Melanoma.

S. Perez, C. Baxevanis, I. Voutsas, 2017, Anticancer research.

Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece.

K. Syrigos, G. Mountzios, D. Mavroudis, 2022, Future oncology.

Clinical Outcomes Beyond 1L EGFR-TKI Progression in mNSCLC: Final Results of the Real-World Study ‘LUNGFUL’

M. Karamouzis, K. Syrigos, V. Georgoulias, 2023, AntiCancer Research.

Subgroup efficacy evaluation of the AE37 HER2 vaccine in breast cancer patients in the adjuvant setting.

E. Mittendorf, G. Peoples, J. Litton, 2017 .

Immune profiling of melanoma tumors reflecting aggressiveness in a preclinical model

S. Perez, C. Baxevanis, I. Voutsas, 2017, Cancer Immunology, Immunotherapy.